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Abstract
The histone deacetylase inhibitor suberoylanilide hydroxamic acid, known as vorinostat, is a 
promising anti-cancer drug with a unique mode of action; however, it is plagued by low water 
solubility, low permeability, and suboptimal pharmacokinetics. In this study, poly(ethylene 
glycol)-b-poly(DL-lactic acid) (PEG-b-PLA) micelles of vorinostat were developed. Vorinostat’s 
pharmacokinetics in rats were investigated after intravenous (i.v.) (10 mg/kg) and oral (50 mg/kg) 
micellar administrations and compared to a conventional PEG400 solution and methylcellulose 
suspension. The micelles increased the aqueous solubility of vorinostat from 0.2 mg/ml to 8.15 ± 
0.60 mg/ml and 10.24 ± 0.92 mg/ml at drug to nanocarrier ratios of 1:10 and 1:15, respectively. 
Micelles had nanoscopic mean diameters of 75.67 ± 7.57 nm and 87.33 ± 8.62 nm for 1:10 and 
1:15 micelles, respectively, with drug loading capacities of 9.93 ± 0.21% and 6.91 ± 1.19 %, and 
encapsulation efficiencies of 42.74 ± 1.67% and 73.29 ± 4.78%, respectively. The micelles 
provided sustained exposure and improved pharmacokinetics characterized by a significant 
increase in serum half-life, area under curve, and mean residence time. The micelles reduced 
vorinostat clearance particularly after i.v. dosing. Thus, PEG-b-PLA micelles significantly 
improved the oral and intravenous pharmacokinetics and bioavailability of vorinostat, which 
warrants further investigation.
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Block copolymers spontaneously form nanoscopic micelles in water, and they are efficient 
solubilizing agents for poorly water soluble drugs. Such ability originates from a 
hydrophobic core that serves as a reservoir of the drug molecules incorporated by chemical, 
physical or electrostatic interactions.1 The core is sterically stabilized by a hydrophilic 
corona, and the resulting micelles are kinetically stable when diluted below the critical 
micelle concentration because of chain entanglement and slow unimer exchange. Beyond 
solubilization, block copolymer micelles can retain the drug leading to prolonged in vivo 
circulation times. The nanocarriers are sufficiently large to avoid renal excretion, yet small 
enough to bypass filtration by interendothelial cell slits in the spleen.2 In addition, they have 
the potential for passive drug targeting to solid tumors via the enhanced permeability and 
retention (EPR) effect.3
Histone deacetylase (HDAC) is an enzyme that removes acetyl groups from lysine residues 
of proteins, including histones and transcription factors.4 Certain cancers overexpress 
HDACs resulting in over-compaction of the histone-DNA complex and repression of gene 
transcription for an array of genes including those for cell-cycle control, apoptosis, and 
tumor suppression.5 The HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA, 
vorinostat, Fig. 1A), is used in the treatment of cutaneous T-cell lymphoma (CTCL).6,7 
Vorinostat is marketed by Merck & Co., Inc. as an oral capsule under the brand name 
Zolinza®.5 Although the therapeutic potential of vorinostat is great 8,9,10, vorinostat is 
plagued by poor aqueous solubility (0.2 mg/ml) and low permeability (a log partition 
coefficient of 1.9) as indicated by its Class IV designation in Biopharmaceutics 
Classification System (BCS). 11 Because of this, development of a parenteral formulation of 
vorinostat has been hindered. For instance, in early clinical studies, the intravenous (i.v.) 
formulations of vorinostat were dissolved in sodium hydroxide, adjusted to pH 11.2, and 
administered over a two hour infusion.12 Other attempts to develop a parenteral formulation 
of vorinostat are limited but include a cyclodextrin formulation.11
Vorinostat is also plagued by suboptimal pharmacokinetics including low bioavailability 
(43% for humans and 11% for rats), extensive serum clearance, and a short elimination half-
life of approximately 2 hours in both animal and human studies. 5,13,14,4,15 Much of the 
short half-life and limited overall exposure of vorinostat is related to its rapid metabolism, 
which is its predominate route of elimination.13 Vorinostat is metabolized via two metabolic 
pathways including glucuronidation and hydrolysis followed by β-oxidation. These 
pathways produce two inactive metabolites, a vorinostat glucuronide and a vorinostat 
hydrolysis metabolite, 4-anilino-4-oxobutanoic acid, both of which are excreted in the 
urine.16 Therefore, it is of medical importance to develop novel formulations of vorinostat 
for both oral and parenteral administrations that improve solubility and the overall 
disposition profile of vorinostat.
Among the commonly used copolymers, poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-
PLA, Fig. 1B) has been selected to develop micellar formulations of vorinostat because it’s 
polymer backbone is based on biodegradable and biocompatible poly(lactide) (PLA) and 
poly(ethylene glycol) (PEG), and PEG-b-PLA is reported to increase the drug aqueous 
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solubility, reduce the burst effect, and prolong the in vivo residence time of drugs due to 
steric stabilization against opsonization and subsequent phagocytocis.17,18,19,20 As well, 
degradation products of PEG–PLA block copolymer can enter the tricarboxylic acid cycle or 
be eliminated by the kidney.21 In addition, the reversal of multiple drug resistance by PEG-
b-PLA micelles was proven as a major reason of the relevance of paclitaxel uptake by tumor 
cells in vitro.22 Consequently, PEG-b-PLA is being widely investigated as a nanocarrier of 
different sparingly soluble drugs including anticancer agents. Moreover, PEG-b-PLA 
micelles have entered phase III clinical trials as a substitute for toxic Cremophor® EL in the 
delivery of paclitaxel in cancer therapy. 23,24
Therefore, it was warranted to develop, characterize, and optimize novel nanoformulations 
of vorinostat using the PEG–b-PLA nanocarrier. In this study, the pharmacokinetics of 
vorinostat in rat serum and urine were investigated following i.v. and oral administrations 




Vorinostat and daidzein were purchased from LC laboratories (Woburn, MA, USA). 
Poly(ethylene glycol)-b-poly(DL-lactic acid) (PEG–b-PLA) block copolymer of PEG/PLA 
ratio of 5000/2000 was purchased from Polymer Source Inc. (Dorval, Quebec, Canada). 
HPLC-grade acetonitrile and water were purchased from J.T. Baker (Philipsburg, NJ, USA). 
Other chemicals were of analytical grade. Healthy male Sprague-Dawley rats with an 
average body weight of ca. 280 g were obtained from Simonsen Labs (Gilroy, CA, USA).
Preparation of vorinostat loaded PEG-b-PLA micelles
Vorinostat loaded PEG-b-PLA micelles were prepared at drug to copolymer ratios of 1:10 
and 1:15. Both vorinostat and PEG-b-PLA were dissolved in a minimum volume of 
tetrahydrofuran and acetone mixture in a ratio of 4:1, respectively, and added drop-wise at a 
rate of 50 µL/min to vigorously stirred ddH2O. Organic solvents then were removed by 
stirring under a nitrogen purge overnight. After removing the organic solvents, PEG-b-PLA 
micelles were passed through a 0.22-µm polyethersulfone filter to remove insoluble material 
and unincorporated drug.25 Micellar solutions were further concentrated by rotary 
evaporation to obtain vorinostat concentrations > 8 mg/ml, which was suitable for dosing 
volumes of ≤ 0.5 ml intravenously (10 mg/kg) and ≤ 2 ml orally (50 mg/kg) using rats with 
an average weight of 280 g.
Characterization of vorinostat loaded PEG-b-PLA micelles
The formation of PEG-b-PLA micelles was determined by size exclusion chromatography 
(SEC) using a Shimadzu 2010CHT system with 0.8 ml/min ddH2O as the mobile phase on a 
Shodex OHpak-806 HQ column (Showa Denko America, NY) thermostated at 40°C. Peaks 
were detected using an evaporative light scattering detector (ELSD-LTII, Shimadzu, 
Lenexa, KS). Narrow molecular weight distribution polyethylene glycols (Scientific 
Polymer Products, Ontario, NY) were used as standards for SEC analysis. To confirm the 
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drug was encapsulated in the micelles, SEC peak fractions were collected and dried by 
Speed-Vap. The dried micelle fractions were redissolved in acetonitrile and then analyzed 
by reversed-phase HPLC. The system was identical to the above but with UV detection (254 
nm) and 0.8-mL/min acetonitrile:methanol:water:trifluoroacetic acid (32:32:36:0.1) mobile 
phase on an ODS-100 C18 5-µm x 150-mm column (Tosoh, Tessenderlo, Belgium) 
thermostated to 40°C.
Measurements of micelle size were performed using Dynamic Light Scattering (DLS) with a 
Malvern Nano ZS instrument and DTS software (Malvern Instruments Ltd, Malvern, 
Worcestershire, UK). The loading efficiency (LE) and entrapment efficiency (EE) of 
vorinostat in PEG-b-PLA micelles were calculated according to the following equations:26
Vorinostat concentration in the prepared micelles was determined with a method previously 
validated at our laboratory that is described below.27 The micelles solution was diluted to a 
range within our calibration curve before addition of the internal standard. The vorinostat-
PEG-b-PLA micelles used for characterization were prepared as detailed above. The loading 
efficiency (LE) was calculated according to the above equation using micelles dried to 
constant weight.
The in vitro stability of the micelles was determined over a period of 5 days, the same period 
of the pharmacokinetic study, by measuring the micelle size daily by DLS and measuring 
drug incorporation after filtration using the validated LC/MS method.
Surgical procedures
Male Sprague-Dawley rats (ca. 280 g) from Simonsen Labs (Gilroy, CA, USA) were 
acclimated for a minimum of 3 days in temperature-controlled rooms with a 12 h light/dark 
cycle and given food (Purina Rat Chow 5001) and water ad libitum. The day before the 
pharmacokinetic experiment, the right jugular veins of the rats were catheterized with sterile 
silastic cannula (Dow Corning, Midland, MI, USA) under isoflurane anesthesia via 
procedures previously published.28 This involved exposure of the vessel prior to cannula 
insertion. After cannulation, Intramedic PE-50 polyethylene tubing (Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA) connected to the cannula was exteriorized through the 
dorsal skin. The cannula was flushed with 0.9% saline. The animals were transferred to 
metabolic cages and fasted overnight. Animal use protocols were approved by The 
Institutional Animal Care and Use Committee at Washington State University, in 
accordance with “The Guide for Care and Use of Laboratory Animals” (National Academy 
Press, revised 1996).
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On the days of the experiment, the animals were dosed intravenously (10 mg/kg) via cannula 
with vorinostat in polyethylene glycol 400 (PEG400) as a control or vorinostat micelles 
using PEG-b-PLA at two different drug to nanocarrier ratios (1:10 and 1:15) (n = 5 for each 
treatment group). The rats were given ≤ 0.5 ml of each formulation as an i.v. bolus via 
cannula. PEG 400 was given intravenously in 0.5 ml of dosing solution. Aqueous solution of 
micelles was dosed intravenously in volume ranged from 0.2 to 0.4 ml. The cannula was 
flushed with normal saline after each IV dose administration. For oral treatment, the rats 
were administered vorinostat (50 mg/kg) as a suspension in 2% methylcellulose as control or 
as a micelle solution via oral gavage (n = 5 for each treatment group). The rats were given ≤ 
2 ml of each formulation orally as a single dose. Vorinostat as 2% MC suspension was given 
orally in 0.5 to 1 ml. For orally dosed micelles solution ranging from 1.04 to 1.93 ml was 
used.
After dosing, serial blood samples (ca. 0.30 ml) were collected from the cannula at 0, 1, 15 
and 30 min, then 1, 2, 4, 6, 12, 24, 48, 72, 96, and 120 h after i.v. administration, or at 0, 15 
and 30 min, then 1, 2, 4, 6, 12, 24, 48, 72, 96, and 120 h after oral administration, and then 
the cannula was flushed with 0.9% saline. After dosing and after each serial blood sampling, 
blinded observers were present to record any visible behavior, bleeding, or change in overall 
appearance of the animal as signs of acute toxicity. Each blood sample was collected into 
regular polypropylene microcentrifuge tubes and following centrifugation; the serum was 
collected and stored at –20°C until analyzed. Urine samples were collected overnight (0 hr 
sample) and over the time intervals of 0–2, 2–6, 6–12, 12–24, 24–48, 48–72, 72–96 and 96–
120 h following both i.v. and oral administration and were stored at – 20°C until analyzed.
LC/MS quantitative assay of vorinostat
Vorinostat concentrations in the prepared micelle solution and collected serum and urine 
samples were determined using a reversed-phase HPLC method with ESI-mode mass 
spectrometry detection that was previously validated by our laboratory. A Shimadzu 
LCMS-2010 EV liquid chromatograph mass spectrometer system (Kyoto, Japan) connected 
to the HPLC portion consisting of two LC-10AD pumps, a SIL-10AD VP auto injector, a 
SPD-10A VP UV detector, and a SCL-10A VP system controller was used. Data analysis 
was accomplished using Shimadzu LCMS Solutions Version 3 software. The mass 
spectrometer conditions consisted of a curved desolvation line (CDL) temperature of 200°C 
and a block temperature of 200°C, a detector voltage of 1.5 kV, and nitrogen nebulizing gas 
at 1.5 L/min. The analytical column used was a Phenomenex Luna C18 (2) (250 × 4.60 mm, 
i.d. 5 µm). The mobile phase consisted of acetonitrile, water, and formic acid (30:70:0.1, 
v/v/v), and it was filtered (0.2 µm) and degassed under reduced pressure prior to use. 
Separation was carried out isocratically at a flow rate of 0.6 ml/min. To the micelles 
solution, serum or urine (100 µl), and 50 µl of internal standard solution, daidzein (100 µg/
ml), was added. The mixture was vortexed for 30 s (Vortex Genie-2, VWR Scientific, West 
Chester, PA, USA). To serum samples, 1 ml of cold acetonitrile (–20°C) was added to 
precipitate serum proteins. Urine samples were extracted with 0.5 ml of methanol. Samples 
were then vortexed for 30 s and centrifuged at 10,000 rpm for 5 min (Beckman Microfuge 
centrifuge, Beckman Coulter Inc., Fullerton, CA, USA). The serum supernatant and all other 
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samples were then evaporated to dryness by a stream of nitrogen gas. The residue was 
reconstituted with 100 µl of mobile phase, vortexed for 30 s, recentrifuged, supernatant 
transferred to HPLC vials, and 10 µl was injected into the LC/MS system. Quantification 
was based on calibration curves obtained using vorinostat with an internal standard, and the 
data were fitted using unweighted least squares linear regression. Vorinostat and the internal 
standard, daidzein were monitored in selected ion monitoring (SIM) positive mode at m/z 
265 and 255, respectively. In addition, the assay allowed monitoring of both a 
glucuronidated metabolite (vorinostat-O-glucuronide) and a hydrolysis metabolite (4-
anilino-4-oxobutanoic acid) via the SIM positive mode at m/z 441 and 194, respectively. The 
metabolites were monitored assuming equal ionization of the metabolites with vorinostat. 
Metabolite concentrations in serum and urine were estimated using the standard curve of 
vorinostat in the respective matrix.
Pharmacokinetic analysis
Pharmacokinetic analysis was completed using data from individual rats for which the mean 
and standard error of the mean (SEM) were calculated for each group except for Tmax which 
was represented as median and range. Pharmacokinetic parameters were estimated using 
WinNonlin® (version 1.0) using noncompartmental analysis. The half-life of the terminal 
elimination phase (t1/2) was calculated using the following equation: t1/2 = 0.693/KE. The 
area under the concentration time curve (AUC0-Clast) was calculated using the linear/
logarithmic trapezoidal method. Summation of AUC0–Clast and the concentration at the last 
measured point divided by KE yielded AUC0–∞ (AUC0–Clast + Clast/KE). Mean residence 
time (MRT) was calculated by dividing AUMC0-∞ (area under the first moment curve) by 
AUC0-∞. Clearance (CL) was estimated using the equation of CL= D/AUC0-∞, where D is 
the dose. Volume of distribution (Vss) was calculated as CL x MRTlast for IV formulations. 
For oral formulations, Vss/F was calculated as Dosepo/AUCpo x MRTIV. The fraction 
excreted in urine unchanged (Fe) was calculated by dividing the total cumulative amount of 
vorinostat excreted in urine (∑Xu) by the dose, renal clearance (CLrenal) by multiplying Fe 
by CL, and non-renal clearance (CLNR) by subtracting CLrenal from CL. The Cmax and 
corresponding Tmax were obtained directly from the observed data. Absolute oral 
bioavailability (F) was calculated from serum data in comparison to i.v. PEG4000 data using 
the relationship F (%) = [(doseiv × AUC0-∞, oral)/ (doseoral × AUC0-∞, iv)] × 100.
Statistical analysis
Micelle characterization data were represented as mean and standard deviation (mean ± SD) 
of triplicate determinations. Pharmacokinetic parameters were reported as mean and 
standard error of the mean (mean ± SEM) of replicate determinations, n = 5. 
Pharmacokinetic results were statistically analyzed based on one-way analysis of variance 
(ANOVA) test followed by Tukey-Kramer test to compare between pairs. This statistical 
analysis was computed using GraphPad InStat version 3.0 (GraphPad Software, Inc., San 
Diego, CA, USA).
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Micelles appeared as a distinct peak on SEC, with a retention time of 7.7 min for the PEG-b-
PLA micelles (7,050 Da using PEG standards) and 12.1 min for the free polymer (unimers) 
(Fig. 1). The micelle fractions were collected and assayed for drug content by HPLC with 
UV detection. Vorinostat was found in the micelle SEC peak (5.5 to 7.5 mL) but not the 
unimer peak, and the HPLC retention time (4.92 min) was identical to the standard with no 
additional peaks.
Formulation of vorinostat with PEG-b-PLA increased the aqueous solubility from 0.2 mg/
ml11 to 8.15 ± 0.60 mg/ml (41-fold) and 10.24 ± 0.92 mg/ml (51-fold) at drug to nanocarrier 
ratios of 1:10 and 1:15, respectively. Mean diameters as determined by DLS were 75.67 ± 
7.57 nm for 1:10 micelles and 87.33 ± 8.62 nm for 1:15 micelles. The loading efficiency 
(LE) for 1:10 and 1:15 micelles were 9.93 ± 0.21% and 6.91 ± 1.19 %, respectively. The 
entrapment efficiency (EE) of vorinostat-loaded micelles at a drug to carrier ratio of 1:15 
(73.29 ± 4.78%) was higher than that of micelles prepared using 1:10 drug to carrier ratio 
(42.74 ± 1.67%). In agreement, it has been reported that with the increase in feeding 
paclitaxel in PEG-PLA micelles from 10% to 50%, encapsulation efficiency decreased from 
98% to 63%.29
Micelle solutions at both drug to carrier ratios, 1:10 and 1:15, were stable in size and drug 
loading for 5 successive days after preparation when stored at 4°C. The average diameters 
for determinations over the five days were 82.20 ± 10.64 nm and 90.40 ± 8.91 nm versus 81 
nm and 89 nm within 2 h after preparation for 1:10 and 1:15 micelles, respectively. The 
average concentration for determinations over the five days was 7.92 ± 0.53 mg/ml and 
10.03 ± 0.71 mg/ml versus 8.15 mg/ml and 10.24 mg/ml within 2 h after preparation for 
1:10 and 1:15 micelles, respectively. The micelle solutions were prepared the day prior to 
the pharmacokinetic study after reexamination of the micelle size and vorinostat 
concentration. The high stability of these micelles may be attributed to the large PEG/PLA 
fraction (5000/2000); it has been reported that the greater the molecular chain length in 
PEG-b-PLA nanoparticles, the more stable the structure will be.21 We attempted to 
formulate vorinostat with micelles of 5000/6700 PEG/PLA using the same methods, but the 
micelles were unstable. A white sediment formed within an hour with a subsequent decrease 
in vorinostat concentration in the filtered supernatant. As will be discussed below, the PEG-
b-PLA micelles showed significant in vivo stability indicated by prolonged exposure of 
vorinostat to the systemic circulation over this period.
Pharmacokinetics of polymeric micellar vorinostat in rat serum
Blinded observers did not report any adverse effects of the tested formulations over the 
length of the experiments.
Both i.v. PEG-b-PLA micelle formulations substantially altered the serum pharmacokinetics 
compared to PEG400 (control) (Fig. 2, Table 1). Vorinostat in PEG400 solution was rapidly 
eliminated to concentrations below detection limits after 2 h post-dosing (Fig. 2A and B). In 
accordance, the vorinostat control formulation demonstrated a short half-life (t1/2 = 0.61 ± 
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0.15 h), low area under curve (AUC0-∞ = 2.48 ± 0.98 µg.h/ml) and a rapid serum clearance 
(CL = 7.64 ± 2.54 l/h/kg) (Table 1). The high volume of distribution at steady state (Vss = 
2.19 ± 0.84 l/kg) exceeded the total body water (0.6 l/kg) of a rat indicating that the drug 
was extensively distributed. Similar results have been reported for vorinostat following i.v. 
administration to rats at a dose of 2 mg/kg.13 Extensive distribution of vorinostat in control 
formulation may be explained in part by its high tissue uptake due to its high lipid solubility. 
Another HDAC inhibitor, kenedine 91, has extensive distribution that was attributed to its 
high lipid solubility.30 High distribution of vorinostat to the liver as has been reported in 
other studies,13 which may also account for the extensive distribution of the drug.
The micelle encapsulated vorinostat showed a sustained retention in vivo of up to 48 h for 
1:10 micelles and 120 h for 1:15 micelles (Fig. 2A) after i.v. administration. Micellar 
formulations of 1:10 and 1:15 PEG-b-PLA increased vorinostat’s t1/2 to 54.46 ± 18.45 h and 
112.02 ± 19.52 h, respectively (Table 1). Compared to vorinostat in PEG400, the micelle 
carrier increased the AUC0-∞ values in serum by 2.7-fold for 1:10 micelles and 15.7-fold 
for those prepared at 1:15 ratio of drug to nanocarrier. The CL of vorinostat decreased by 
4.6-fold and 28.9-fold for 1:10 and 1:15 micelle formulations, respectively, compared to 
vorinostat in PEG400. Both renal (CLrenal) and non-renal (CLNR) clearances were greatly 
reduced by encapsulation in micelles. This implies that these micelles hindered hepatic 
biotransformation and glomerular filtration of vorinostat. The reduction in CLrenal of 
vorinostat by 1:15 micelles was much higher than that seen with the 1:10 formulation. It has 
been reported that increases in polymer size (molecular weight or hydrodynamic volume) 
can lead to increases in blood circulation half-life and decreased renal clearance.31,32 This 
relationship is generally non-linear and the change in blood circulation half-life and renal 
clearance with respect to polymer size can be dramatic.31 This holds true when comparing 
polymers above the renal filtration cut off.31,33
The micelle formulations increased the mean residence time (MRT) of vorinostat by 107-
fold and 232-fold and Vss by 7.42- and 4.47-fold at drug to carrier ratios of 1:10 and 1:15, 
respectively (Table 1).Inhibition of P-glycoprotein (Pgp) at the cell membrane by PEG-b-
PLA polymeric micelles and subsequent release of core-encapsulated drug into the cell 
membrane to be internalized into the cell via endocytosis may explain the higher values of 
Vss compared to the control formulations.22 Vorinostat loaded PEG-b-PLA micelles given 
orally showed significantly altered pharmacokinetic parameters from those of the 2% MC 
control formulation (Table 2, Fig. 2C and D). Both types of micelles substantially 
lengthened the MRT of vorinostat from 5.35 h in MC, to 128.79 and 132.76 h for the 1:10 
and 1:15 formulations, respectively. Compared to vorinostat suspension, the block 
copolymer significantly increased the AUC0-∞ values of vorinostat in serum by 7.76- and 
19.65-fold for 1:10 and 1:15 micelles, respectively. The serum t1/2 of vorinostat in 1:10 and 
1:15 polymeric micelles (70.86 ± 7.11 h and 79.98 ± 13.73 h, respectively) was significantly 
longer than that of vorinostat in 2% MC suspension (3.45 ± 0.84 h). A decrease in total 
clearance (Cl/F) vorinostat by 6.97-fold for 1:10 micelles and 18.77-fold for those with 1:15 
drug to nanocarrier loading was observed, when compared to 2% MC suspension (Table 2). 
The volume of distribution (Vss/F) of vorinostat in micellar formulations given orally was 
increased by 5.43- and 7.32-fold for 1:10 and 1:15 micelles, respectively. These changes in 
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clearance and volume of distribution seen with micelles given orally maybe attributed to 
modification in bioavailability of vorinostat.
Following oral administration of the control and nanocarrier formulations, rapid absorption 
of vorinostat was evident with no statistically significant differences in time to concentration 
maximum (Tmax) between the formulations seen (Table 2). The orally administered 1:15 
micelles significantly increased the concentration maximum (Cmax = 0.453 ± 0.087 µg/ml) 
by 2.29-fold compared to the 2% MC suspension. No significant change in the Cmax of the 
1:10 micelles was noted compared to the control formulation. The absolute oral 
bioavailability (F) of the control formulation was low (6.41 ± 0.53%). Previous 
pharmacokinetic studies also reported a short Tmax (0.3 ± 0.1 h) and low oral bioavailability 
(11%) of vorinostat following oral (10 mg/kg) dosing of rats.13 In another study, a short 
Tmax (0.17 ± 0.0 h) and low oral bioavailability (6.9%) of vorinostat following oral 
administration of (5 mg/kg) to Wistar rats were also documented.14 Micellar systems at drug 
to carrier ratios used, 1:10 and 1:15, significantly increased F by 9.16- and 15.40-fold, 
respectively (Table 2).
The serum disposition and pharmacokinetic parameters obtained following i.v. and oral 
administration of control and nanocarrier formulations reveals that the micellar systems 
provide improved delivery and more sustained exposure. These effects were more 
pronounced with 1:15 micelles probably due to the higher of PEG-b-PLA micelles on 
decrease of drug loading as has been reported in other studies.34 In previous reports, PEG-
PLA was reported as a potential delivery system to achieve sustained release and 
accumulation in tumors of some poorly soluble anticancer drugs. For example, paclitaxel-
loaded PEG-b-PLA micelles showed more sustained release in vitro and increased cellular 
accumulation of paclitaxel in paclitaxel-resistant human ovarian cell line A2780/T compared 
with free paclitaxel due to a proven inhibition of Pgp function by PEG-b-PLA micelles.22
Following i.v. and oral administrations, only the hydrolysis metabolite of vorinostat (4-
anilino-4-oxobutanoic acid) could be detected in rat serum for up to 12 h (Fig. 3). Both 1:10 
and 1:15 PEG-b-PLA micelles decreased the levels of this metabolite in serum compared to 
the controls, which suggests PEG-b-PLA micelles as a protectant of the drug against the 
hepatic metabolism.
Pharmacokinetics of polymeric micellar vorinostat in rat urine
Following i.v. administration, the total amount excreted in urine plot (Fig. 4A) demonstrates 
that small amounts of vorinostat are excreted in the urine with both the control and micelle 
formulations. The fraction excreted unchanged (Fe) of vorinostat from PEG400 (7.17 ± 0.96 
%) was reduced by 2.26- and 8.63-fold by the micellar systems at 1:10 and 1:15 drug to 
nanocarrier ratios, respectively (Table 1). In addition, CLrenal of vorinostat was decreased by 
10.68- and 246.91-fold following i.v. administration of the 1:10 and 1:15 micelles (Table 1). 
These micelles may prevent filtration in the glomeruli, as micelles are larger than the 
glomeruli filtration limit.
The rate elimination plots (Fig. 4B) indicate similar urinary excretion rates of vorinostat 
from PEG400, 1:10 and 1:15 micelles. In accordance, the amount remaining to be excreted 
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(ARE) plots (Fig. 4C) show that vorinostat was excreted at similar rates and most of the 
renally eliminated vorinostat was excreted by 72 h, 24 h and 6 h post-dosing with vorinostat 
in PEG400 as control, 1:10 and 1:15 micelles, respectively.
Following oral administration, the total amount excreted in urine plot (Fig. 5A) indicates 
that vorinostat from 2% MC suspension was excreted in higher amounts compared to the 
micellar systems. The majority of the renally eliminated vorinostat was excreted by 12 h in 
case of the control and 1:10 micelles, and by 6 h for the 1:15 micelles. The fraction excreted 
unchanged (Fe) of vorinostat from 2% MC suspension (0.53 ± 0.04 %) was lowered by 1.73- 
and 29.33-fold by the 1:10 and 1:15 micelles, respectively (Table 2). The 1:10 and 1:15 
micelles given orally decreased the renal clearance (CLrenal/F) of vorinostat by 11.67- and 
541.38-fold compared to the control (Table 2). The observed changes in CLrenal/F following 
the oral administration of micellar formulations likely can be attributed to differences in 
vorinostat bioavailability. A possibility of absorption of intact micelles through energy 
dependent internalization35,36 or other polymeric degradation component-drug conjugates37 
in the gut has been demonstrated. These components remain too large to be filtered by the 
kidney and exhibit modified drug release via drug cleavage.38 Similar polymeric conjugates 
of vorinostat might have hindered glomerular filtration.
Following i.v. and oral administrations, ARE is maximum for the control formulation in 
spite of the higher excretion rate compared to micelle formulations. This is probably due to 
the larger amount of vorinostat originally available to be excreted unchanged in the urine. 
Hence, excretion occurred over a longer period of time and vorinostat was detected in the 
urine until later times than observed with micelles, which appear to hinder filtration in 
glomeruli as indicated by lower CLrenal and Fe in comparison with control formulations.
Control formulations demonstrated shorter MRTs than that noticed for micelles after i.v. 
(0.66 ± 0.20 h) and oral (5.35 ± 1.25 h) administrations (Tables 1 and 2, respectively). 
However, vorinostat was excreted in the urine even at later time points. A very small amount 
of vorinostat in comparison to the dose was excreted unchanged in the urine as indicated by 
values of Fe for control formulations after i.v. (7.17 ± 0.96% ) and oral (6.41 ± 0.53 %) 
dosing (Tables 1 and 2, respectively). In addition, the majority of renally eliminated 
vorinostat was excreted unchanged in the urine early within 2 h after i.v. dosing (Fig. 4A) 
and 6 h following oral administration (Fig. 5A).
Both hydrolysis and glucuronidated metabolites were detected in urine. Distinctly lower 
urinary excretion of vorinostat hydrolysis and glucuronide metabolites were excreted in 
urine after i.v. administration (Fig. 6A and B, respectively) than that observed following 
orally administered formulations (Fig. 6C and D, respectively). These results can be 
explained by the predominant first pass metabolism of vorinostat after oral dosing.13 A 
decrease in metabolite excretion in urine following i.v. and oral administration of micellar 
formulations was observed (Fig. 6) possibly due to a protection by micellar system against 
enzymes in the liver responsible for vorinostat metabolism.
Recent reports using a rat renal proximal tubular cell line suggest possible renal toxicity of 
vorinostat, through protein acetylation and a decrease of antiapoptotic proteins.39,39 Despite 
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the low percentage of the drug being excreted unchanged in urine as reported in this study 
and other studies,13 some signs of renal toxicity including increased blood creatinine and 
proteinuria have been reported in some clinical studies of vorinostat.40,41 In another study, 
the maximum tolerated dose of vorinostat decreased progressively as hepatic dysfunction 
worsened, which was associated with possible toxicity due to vorinostat metabolites.42 The 
reduction in renal elimination of vorinostat in the micellar formulations may reduce renal 
exposure and therefore reduce renal toxicity particularly after i.v. administration.
Vorinostat is a class IV drug with low aqueous solubility and permeability. Hence, an 
increased bioavailability may be expected with significantly increased solubility and 
permeability. The dramatically enhanced aqueous solubility of vorinostat in PEG-b-PLA 
micelles (> 40 times vs. intrinsic solubility) can facilitate development of parenteral 
formulations of vorinostat and be considered as a benefit of oral micellar formulations with 
respect to bioavailability. The improvement of bioavailability via enhancement of aqueous 
solubility in nanoparticles has been seen in other drug formulations. For instance, release of 
genistein from nanoparticles formed with Eudragit® E100 was two times greater than that 
from the conventional capsules and the relative bioavailability compared with the reference 
suspension was 241.8% after oral administration (100 mg/kg) to fasted rats.43,43 The 
reported effects of PEG-b-PLA micelles on intestinal P-glycoprotein efflux pump also may 
have increased the drug permeability and enhanced the oral bioavailability.44 The micelles 
protect against hepatic biotransformation and first pass metabolism as indicated by lower 
amounts of metabolites in serum and urine, which may also account for the increased 
bioavailability of micellar vorinostat. The overall effects of micellar formulations on 
vorinostat bioavailability is likely due to a combination of these factors.
Conclusions
Micelle PEG-b-PLA formulations of vorinostat were developed that increased the water 
solubility by over 40-fold. PEG-b-PLA micellar systems improved the pharmacokinetics of 
vorinostat in rats and invoked a marked change in its biological fate characterized by 
statistically significant increases in serum half-life, area under curve, mean residence time, 
and bioavailability. These effects were more pronounced with 1:15 micelles possibly due to 
higher entrapment efficiency and more stable micelles in vivo compared to 1:10 micelles. 
The longer systemic residence of vorinostat in micelles was possibly due to a pronounced 
sustained exposure in vivo. Therefore, PEG-b-PLA micelles of vorinostat may be a 
nanoparticulate delivery system with improved disposition which could potentially lower 
hepatic toxicities than conventional parenteral and oral formulations. Reduced renal 
exposure particularly after i.v. dosing could also facilitate lower renal toxicity.
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SEC chromatography of PEG-b-PLA micelle in water mobile phase at 0.8 mL/min. (1A) 
structure of vorinostat; (1B) structure of poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-
PLA).
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Concentration-time profiles of vorinostat in rat serum after intravenous administration of 
vorinostat up to 120 h (A) with zoom in up to 6 h (B). Concentration-time profile of 
vorinostat in rat serum after oral administration of vorinostat up to 120 h (C) with zoom up 
to 24 h (D). The intravenous and oral doses of vorinostat for all formulations were 10 mg/kg 
and 50 mg/kg, respectively (mean ± SEM, n = 5 per group).
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Concentration-time profiles of vorinostat hydrolysis metabolite in rat serum after 
intravenous administration of vorinostat (A) and after oral administration of vorinostat (B). 
The intravenous and oral doses of vorinostat for all formulations were 10 mg/kg and 50 
mg/kg, respectively (mean ± SEM, n = 5 per group).
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(A) Total amount excreted in urine plot, (B) urinary rate plot, and (C) amount remaining to 
be excreted in urine (ARE) plot of vorinostat after intravenous administration of vorinostat 
to rats at a dose of 10 mg/kg (mean ± SEM, n = 5 per group).
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(A) Total amount excreted in urine plot, (B) urinary rate plot, and (C) amount remaining to 
be excreted in urine (ARE) plot of vorinostat after oral administration of vorinostat to rats at 
a dose of 50 mg/kg (mean ± SEM, n = 5 per group).
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Total amount excreted in urine plots of (A) the hydrolysis metabolite and (B) the 
glucuronide metabolite following intravenous administration of vorinostat. Total amount 
excreted in urine plots of (C) the hydrolysis metabolite, and (D) the glucuronide metabolite 
following oral administration of vorinostat. The intravenous and oral doses of vorinostat for 
all formulations were 10 mg/kg and 50 mg/kg, respectively (mean ± SEM, n = 5 per group).
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Table 1
Pharmacokinetics of Vorinostat after Intravenous Administration to Rats at a Dose of 10 mg/kg (mean ± SEM, 









t1/2 (h) serum 0.61 ± 0.15 54.46 ± 18.45a* 112.71 ± 19.52a***,b*
Fe (%) 7.17 ± 0.96 3.17 ± 0.15a*** 0.83 ± 0.19 a***,b*
CL (l/h/kg) 7.64 ± 2.54 1.66 ± 0.35a* 0.27 ± 0.025a*
CLrenal (l/h/kg) 0.55 ± 0.23 0.05 ± 0.0091a* 0.0022 ± 0.0007a*
CLNR (l/h/kg) 7.09 ± 2.32 1.61 ± 0.34a* 0.26 ± 0.024a**
MRT (h) 0.66 ± 0.20 70.61 ± 21.09a* 153.18 ± 21.52a***,b**
Vss (l/kg) 2.19 ± 0.84 16.28 ± 1.74a 9.82 ± 0.68ab
AUC 0-∞ (µg.h/ml) 2.48 ± 0.98 6.77 ± 1.76 a***,b*** 39.01 ± 3.42
a
Statistically significant difference compared to vorinostat in PEG400 as control.
b




P < 0.01, and
***
P < 0.001.
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Table 2













t1/2 (h) serum 3.45 ± 0.844 70.86 ± 7.106 a*** 79.98 ± 13.73 a***
Fe (%) 0.53 ± 0.042 0.30 ± 0.030a*** 0.02 ± 0.006a***,b***
CL/F (l/h/kg) 56.21 ± 4.414 8.07 ± 1.823 a*** 2.99 ± 0.37a***
CLrenal/F (l/h/kg) 0.29 ± 0.032 0.03 ± 0.007a*** 0.001 ± 0.0002a***
CLNR/F (l/h/kg) 55.92 ± 4.393 8.04 ± 1.816a*** 2.99 ± 0.37a***
MRT (h) 5.35 ± 1.248 128.79 ± 13.489a*** 132.76 ± 18.66a***
Vss/F (l/kg) 15.49 ± 1.22 84.13 ± 19.01a 113.46 ± 13.97a,b
AUC 0-∞ (µg.h/ml) 0.91 ± 0.079 7.09 ± 0.994a* 17.95 ± 2.57a***,b**
F (%) 6.41 ± 0.527 58.72 ± 9.806a** 98.69 ± 15.87a***,b*
Tmax (h) 0.25c, 0.75d 0.25c, 0d 0.50c, 0.75d
Cmax (µg/ml) 0.198 ± 0.020 0.283 ± 0.026 0.453 ± 0.087a*
a
Statistically significant difference compared to vorinostat in 2% w/v methylcellulose suspension as control.
b
Statistically significant difference compared to vorinostat in 1:10 PEG-b-PLA micelles.
c,d




P < 0.01, and
***
P < 0.001.
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